Aptus Pharma intimated BSE of its board meeting on 27th April 2026 to consider audited financial results for the half year/year ended 31st March 2026.
The company's trading window for dealing in its securities is closed and will remain closed until 48 hours after results declaration.
The disclosure is made pursuant to SEBI LODR Regulations 29(1)(a) and 33, and the company's insider trading code.